All In Biotech

Drug Trial Radar · NCT03485729

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

27

Actual

Start

Mar 21, 2018

Primary completion

Jan 19, 2023

Study completion Jan 19, 2023

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Oncoceutics, Inc.
First posted
Apr 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen. Patients with histologically confirmed Type II endometrial cancer, including but not limited to serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologies were eligible. The primary objective of this study was to determine the efficacy of dordaviprone (ONC201) in metastatic type II endometrial cancer. Note: This study was completed by predecessor company, Oncoceutics, Inc.

Conditions

  • Endometrial Cancer Recurrent

Interventions

  • Dordaviprone (ONC201)Drug

    625 mg dordaviprone (ONC201)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival Rate at 2 MonthsTime frame: 2 months (8 weeks); from treatment initiation to 2 months (8 weeks) following treatment initiation

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Rutgers, The State University of New Jersey

    New Brunswick, New Jersey

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.